@article{bf231f94af9c47ecbd8c1ffcb96ae879,
title = "Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics",
abstract = "Introduction Children with chronic medical diseases are at an unacceptable risk of hospitalisation and death from influenza and SARS-CoV-2 infections. Over the past two decades, behavioural scientists have learnt how to design non-coercive € nudge' interventions to encourage positive health behaviours. Our study aims to evaluate the impact of multicomponent nudge interventions on the uptake of COVID-19 and influenza vaccines in medically at-risk children. Methods and analyses Two separate randomised controlled trials (RCTs), each with 1038 children, will enrol a total of approximately 2076 children with chronic medical conditions who are attending tertiary hospitals in South Australia, Western Australia and Victoria. Participants will be randomly assigned (1:1) to the standard care or intervention group. The nudge intervention in each RCT will consist of three text message reminders with four behavioural nudges including (1) social norm messages, (2) different messengers through links to short educational videos from a paediatrician, medically at-risk child and parent and nurse, (3) a pledge to have their child or themselves vaccinated and (4) information salience through links to the current guidelines and vaccine safety information. The primary outcome is the proportion of medically at-risk children who receive at least one dose of vaccine within 3 months of randomisation. Logistic regression analysis will be performed to determine the effect of the intervention on the probability of vaccination uptake. Ethics and dissemination The protocol and study documents have been reviewed and approved by the Women's and Children's Health Network Human Research Ethics Committee (HREC/22/WCHN/2022/00082). The results will be published via peer-reviewed journals and presented at scientific meetings and public forums. Trial registration number NCT05613751.",
keywords = "COVID-19, INFECTIOUS DISEASES, Primary Prevention, Public health",
author = "Bing Wang and Prabha Andraweera and Margaret Danchin and Blyth, {Christopher C.} and Ivo Vlaev and Jason Ong and Dodd, {Jodie M.} and Jennifer Couper and Sullivan, {Thomas R.} and Jonathan Karnon and Nicola Spurrier and Michael Cusack and Dylan Mordaunt and Dimi Simatos and Gustaaf Dekker and Samantha Carlson and Jane Tuckerman and Nicholas Wood and Whop, {Lisa J.} and Helen Marshall",
note = "Funding Information: This work is supported by the National Health and Medical Research Council of Australia (NHMRC Partnership grant APP2014684). Additional in-kind funding is provided by funding partners including the Department of Health, South Australia Government; Department of Health, Victorian Government; Department of Health, Western Australian Government; Women{\textquoteright}s and Children{\textquoteright}s Health Network; Southern Adelaide Local Health Network; Northern Adelaide Local Health Network; Women{\textquoteright}s and Children{\textquoteright}s Hospital Foundation; Department of Trade and Investment, South Australian Government, in support of the NHMRC Partnership grant. Funding Information: This work is supported by the National Health and Medical Research Council of Australia (NHMRC Partnership grant APP2014684). Additional in-kind funding is provided by funding partners including the Department of Health, South Australia Government; Department of Health, Victorian Government; Department of Health, Western Australian Government; Women's and Children's Health Network; Southern Adelaide Local Health Network; Northern Adelaide Local Health Network; Women's and Children's Hospital Foundation; Department of Trade and Investment, South Australian Government, in support of the NHMRC Partnership grant. Funding Information: HM acknowledges support from the National Health and Medical Research Council of Australia: Practitioner Fellowship (APP1155066). CCB acknowledges support from the National Health and Medical Research Council of Australia: Investigator Grant (APP1173163). HM is an independent investigator on clinical trials of investigational vaccines manufactured by pharmaceutical companies including Pfizer, ILiAD Biotechnologies and Merck. The institution at which HM, BW and PA are employed has received funding for investigator-led research from GlaxoSmithKline, Sanofi-Pasteur and Pfizer Vaccines. All authors receive no personal payments from industry. There are no other conflicts of interest to declare. Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.",
year = "2024",
month = feb,
day = "17",
doi = "10.1136/bmjopen-2023-076194",
language = "English",
volume = "14",
journal = "BMJ open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "2",
}